Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments

Current Psychiatry Reports

Volumn 6, Issue 5, 2004, Pages 364-371

  McAllister, Thomas W ^a   Ahles, Tim A ^b   Saykin, Andrew J ^b   Ferguson, Robert J ^b   McDonald, Brenna C ^b   Lewis, Lionel D ^b   Flashman, Laura A ^b   Rhodes, C Harker ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; APOLIPOPROTEIN E; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE INHIBITOR; CYTOTOXIC AGENT; DOXORUBICIN; ERYTHROPOIETIN; FEXOFENADINE; METHOTREXATE; METHYLPHENIDATE; MITOMYCIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; TAXANE DERIVATIVE; VINCA ALKALOID;

ATTENTION; BEHAVIOR THERAPY; BLOOD VESSEL INJURY; BRAIN CANCER; BRAIN DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DEMYELINATION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; GENETIC POLYMORPHISM; HUMAN; LEARNING DISORDER; LEUKOENCEPHALOPATHY; MEMORY DISORDER; META ANALYSIS; MULTIDRUG RESISTANCE; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OTOTOXICITY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR; VASCULITIS;

EID: 9944241778     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0023-y     Document Type: Review

References (94)

1. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001, 9: 12-820.
2. Ahles T: Neuropsychological impact of systemic chemotherapy. Paper presented to the National Cancer Advisory Board National Cancer Institute, 2002.
3. Ferguson RJ, Ahles TA: Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 2003, 3:215-222.
4. Meyers CA, Geara F, Wong PF, et al.: Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 2000, 46:51-55.
5. Olin JJ: Cognitive function after systemic therapy for breast cancer. Oncology 2001, 15:613-618.
6. Rugo H, Ahles TA: The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol 2003, 30:749-762.
7. Wefel JS, Lenzi R, Theriault RL, et al.: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 2004, 100:2292-2299.
8. Saykin AJ, Ahles TA, Schoenfeld JD, et al.: Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc 2003, 9:246.
9. President's Cancer Panel: Cancer Care Issues in the United States: Quality of Care, Quality of Life. Washington, D.C., National Cancer Program, National Cancer Institute, 1999.
10. Ferrell BR, Dow K, Grant M: Measurement of the quality of life in cancer survivors. Qual Life Res 1995, 4:523-531.
11. Barton D, Loprinzi C: Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 2002, 3:S121-127.
12. Silberfarb PM: Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 1983, 34:35-46.
13. Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493.
14. Walch SE, Ahles TA, Saykin AJ: Neuropsychological impact of cancer and cancer treatments. In Psycho-Oncology. Edited by Holland JC, Breitbart W, Jacobson PB, et al. New York: Oxford University Press; 1998:500-505.
15. Anderson-Hanley C, Sherman ML, Riggs R, et al.: Possible cognitive effects of systemic treatment for cancer: A meta-analysis. J Int Neuropsychol Soc 2002, 8:254.
16. Keime-Guibert F, Napolitano M, Delattre JY: Neurological complications of radiotherapy and chemotherapy. J Neurol 1998, 245:695-708.
17. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Reat Rev 1994, 20:191-214.
18. Troy L, McFarland K, Littman-Power S, et al.: Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology 2000, 9:29-39.
19. Saykin AJ, Ahles TA, McDonald BC: Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003, 8:201-216.
20. Quinn Cr, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities J Invest Med 1996, 44:522-530.
21. Madhyastha S, Somayaji SN, Rao MS, et al.: Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 2002, 80:1076-1084.
22. van der Kooy D, Zito KA, Roberts DC: Evidence on the retrograde neurotoxicity of doxorubicin. Neurosci Lett 1985, 53: 215-219.
23. Arnsten AFT: Catecholamine modulation of prefrontal cortical cognitive function. Trends Cognitive Sci 1998, 2: 36-447.
24. Sarter M, Givens B, Bruno JP: The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Brain Res Rev 2001, 35:146-160.
25. Sarter M, Bruno JP: Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 2000, 95:933-952.
26. Sarter M, Bruno JP, Turchi J: Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann N Y Acad Sci 1999, 877:368-382.
27. Thiebaut F, Tsuruo T, Hamada H, et al.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84: 735-7738.
28. Cordon-Cardo C, O'Brien JP, Casals D, et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989, 86:695-698.
29. Can B, Hagenbuch B, Kullak-Ublick GA, et al.: Organic aniontransporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000, 294:73-79.
30. Chang G: Multidrug resistance ABC transporters. FEBS Letters 2003, 555:102-105.
31. Kim RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002, 34:47-54.
32. Marzolini C, Paus E, Budin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
33. Hoffmeyer S, Burk O, von Richter O, et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
34. Kim RB, Leake BF. Choo EF, et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001, 70:189-199.
35. Siddiqui A, Kerb R, Weale ME, et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348: 442-1448.
36. Hagenbuch B, Gao B, Meier PJ: Transport of xenobiotics across the blood-brain barrier. News Physiol Sci 2002, 17: 31-234.
37. Kim RB: Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003, 33(Suppl 2):1-5.
38. Meier PJ, Eckhardt U, Schroeder A, et al.: Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 1997, 26:1667-1677.
39. Marzolini C, Tirona R, Kim R: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004, 205:273-282.
40. Hicks RR, Numan S, Dhillon HS, et al.: Alterations in BDNF and NT-3 mRNAs in rat hippocampus after experimental brain trauma Brain Res Mol Brain Res 1997, 48:401-406.
41. Hicks RR, Zhang L, Dhillon HS, et al.: Expression of trkB mRNA is altered in rat hippocampus after experimental brain trauma Brain Res Mol Brain Res 1998, 59:264-268.
42. Egan MF, Kojima M, Callicott JH, et al.: The BDNF val66met Polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112: 57-269.
43. Lu B, Gottschalk W: Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res 2000, 126:231-241.
44. Poo MM: Neurotrophins as synaptic modulators. Nature Reviews Neuroscience 2001, 2:24-32.
45. Aoyama M, Asai K, Shishikura T, et al.: Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 2001, 164:51-60.
46. Nakayama M, Gahara Y, Kitamura T, et al.: Distinctive four promoters collectively direct expression of brain-derived neurotrophic factor gene. Brain Res Mol Brain Res 1994, 21:206-218.
47. Dias BG, Banerjee SB, Duman RS, et al.: Differential regulation of brain derived neurotrophic factor transcripts by antide-pressant treatments in the adult rat brain. Neuropharmacology 2003, 45:553-563.
48. Timmusk T, Lendahl U, Funakoshi H, et al.: Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. J Cell Biol 1995, 128: 85-199.
49. Kunugi H, Ueki A, Otsuka M, et al.: A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001, 6:83-86.
50. Riemenschneider M, Schwarz S, Wagenpfeil S, et al.: A Polymorphism of the Brain-Derived Neurotrophic Factor (BDNF) is Associated with Alzheimer's Disease in Patients Lacking the Apolipoprotein E E4 Allele. Mol Psychiatry 2002, 7: 82-785.
51. Szekeres G, Juhasz A, Rimanoczy A, et al.: The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 2003, 65:15-18.
52. Chen Y, Lomnitski L, Michaelson DM, et al.: Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 1997, 80:1255-1262.
53. Hartman RE, Laurer H, Longhi L, et al.: Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 2002, 22:10083-10087.
54. Sabo T, Lomnitski L, Nyska A, et al.: Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities Neuroscience 2000, 101:879-884.
55. Laws SM, Clarnette RM, Taddei K, et al.: APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 2002, 7:768-775.
56. Nathoo N, Chetry R, van Dellen JR, et al.: Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: influence of ethnic and regional differences. J Neurosurg 2003, 98:302-306.
57. Nathoo N, Chetty R, van Dellen JR, et al.: Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol Pathology 2003, 56:132-136.
58. Friedman G, Froom P, Sazbon L, et al.: Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999, 52:244-248.
59. Parasuraman R, Greenwood PM, Sunderland T: The apolipoprotein E gene, attention, and brain function. Neuropsychology 2002, 16:254-274.
60. Ahles TA, Saykin AJ, Noll WW, et al.: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003, 12:612-619.
61. McAllister TW, Summerall L: Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders. Curr Psychiatry Rep 2003, 5:400-409.
62. Weinberger DR, Egan MF, Bertolino A, et al.: Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001, 50:825-844.
63. Gainetdinov RR, Jones SR, Fumagalli F, et al.: Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 1998, 26:148-153.
64. Malhotra AK, Kestler LJ, Mazzanti C, et al.: A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002, 159:652-654.
65. Gogos JA, Morgan M, Luine V, et al.: Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998, 95:9991-9996.
66. Liljequist R, Haapalinna A, Ahlander M, et al.: Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 1997, 82:195-202.
67. Gasparini M, Fabrizio E, Bonifati V, et al.: Cognitive improvement during Tolcapone treatment in Parkinson's disease J Neural Transm 1997, 104:887-894.
68. Egan MF, Goldberg TE, Kolachana BS, et al.: Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001, 98: 917-6922.
69. Goldberg TE, Egan MF, Gscheidle T, et al.: Executive subprocesses in working memory: relationship to catechol-O-methyltransferase VAl158Met genotype and schizophrenia. Arch Gen Psychiatry 2003, 60:889-896.
70. Bilder RM, Volavka J, Czobor P, et al.: Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002, 52:701-707.
71. Lipsky RH, Sparling MB, Ryan LM, et al.: Role of COMT Val158Met genotype in executive functioning following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2002, 14: 16.
72. Flashman LA, Saykin AJ, Rhodes CH, et al.: Effect of COMT Val/Met genotype on frontal lobe functioning in traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004, 16:238-239.
73. McAllister TW, McDonald B, Flashman L, et al.: Differential effect of COMT allele status on frontal activation associated with a dopaminergic agonist. J Neuropsychiatry Clin Neurosci 2004, 16:240.
74. Ferguson RJ, Ahles TA: Brief cognitive-behavioral treatment of chemotherapy-associated attention and memory complaints among breast cancer survivors: Pilot data. In Final Program & Rapid Communication Poster Abstracts of the 23rd Annual Scientific Sessions of the Society of Behavioral Medicine. Washington, DC: 2002: 74.
75. Cimprich B: Development of an intervention to restore attention in cancer patients. Cancer Nurs 1993, 16:83-92.
76. Butler R, Copeland D: Additional processes and their remediation in children treated for cancer: A literature review and the development of a therapeutic approach. J Int Neuropsychol Soc 2002, 8:115-124.
77. Ferguson RJ, Mittenberg W: Cognitive behavioral treatment of postconcussion syndrome: a therapist's manual. In Sourcebook of Psychological Treatment Manuals for Adult Disorders. Edited by Van Hasselt VB, Hersen M. New York: Plenum Press; 1996:615-656.
78. Ferguson RJ, Mittenberg W: Cognitive-behavioral treatment of postconcussion syndrome: Multiple case data. Presented at the 30th Annual Convention of the Association for the Advancement of Behavior Therapy, New York, NY. 1996.
79. Prigatano GP: Principles of Neuropsychological Rehabilitation. New York, Oxford University Press, 1999.
80. Sohlberg MM, Mateer CA: Cognitive Rehabilitation: An Integrative Neuropsychological Approach. New York, Guilford Press, 2001.
81. Cicerone K, Dahlberg C, Kalmar K, et al.: Evidence-based cognitive rehabilitation recommendations for clinical practice. Arch Phys Med Rehabil 2000, 8:1596-1615.
82. Gray JM, Robertson I, Pentland B, et al.: Microcomputer-based attentional retraining after brain damage: a randomized group controlled trial. Neuropsychol Rehabil 1992, 2:97-115.
83. Novack TA, Caldwell SG, Duke LW, et al.: Focused versus unstructured intervention for attention deficits after traumatic brain injury. J Head Traum Rehabil 1996, 11:52-60.
84. Niemann H, Ruff RM, Baser CA: Computer assisted attention retraining in head injured individuals: a controlled efficacy study of an out-patient program. J Consult Clin Psychol 1990, 58: 11-817.
85. Sturm W, Wilmes K, Orgass B: Do specific attention deficits need specific training? Neuropsychol Rehabil 1997, 7:81-103.
86. Ethier M, Braun C, Baribeau JMC: Computer-dispensed cognitive-perceptual training of dosed head injury patients after spontaneous recovery. Study 1: speeded tasks. Can J Rehabil 1989, 2:223-233.
87. Wilson B, Robertson IH: A home based intervention for attentional slips during reading following head injury: a single case study. Neuropsychol Rehabil 1992, 2:193-205.
88. Gansler DA, McCaffrey RJ: Remediation of chronic attention deficits in traumatic brain-injured patients. Arch Clin Neuropsychol 1991, 6:335-353.
89. Gray JM, Roberston I: Remediation of attentional difficulties following brain injury: 3 experimental single case studies Brain Injury 1989, 3:163-170.
90. Wood RL: Rehabilitation of patients with disorders of attention. J Head Traum Rehabil 1986, 1:43-53.
91. Rozans M, Dreisbach A, Lenora JJ, et al.: Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002, 20:335-339.
92. Meyers CA, M.A. W, Valentine AD, et al.: Methylphenidate therapy improve cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522-2527.
93. DeLong R, Friedman HP, Friedman N, et al.: Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. J Child Neurol 1992, 7:462-463.
94. Thompson SJ, Leigh L, Christensen R, et al.: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001, 19: 802-1808.